5/22
11:14 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/21
04:18 pm
avte
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Medium
Report
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
5/21
04:15 pm
avte
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Medium
Report
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
5/14
08:46 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Low
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/13
04:34 pm
avte
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights [Yahoo! Finance]
5/13
04:30 pm
avte
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Low
Report
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
4/9
06:02 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
4/1
12:17 pm
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.
3/27
09:20 am
avte
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Medium
Report
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
3/25
04:18 pm
avte
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
3/25
04:10 pm
avte
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Medium
Report
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
3/25
08:45 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $65.00 price target on the stock, up previously from $21.00.
Low
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $65.00 price target on the stock, up previously from $21.00.
3/6
08:11 am
avte
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair [Yahoo! Finance]
Medium
Report
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair [Yahoo! Finance]
3/6
08:00 am
avte
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Medium
Report
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair